ProfileGDS5678 / 1419255_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 78% 78% 76% 78% 80% 83% 80% 83% 79% 78% 78% 82% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4020578
GSM967853U87-EV human glioblastoma xenograft - Control 25.4019978
GSM967854U87-EV human glioblastoma xenograft - Control 35.3966978
GSM967855U87-EV human glioblastoma xenograft - Control 45.2877576
GSM967856U87-EV human glioblastoma xenograft - Control 55.4523978
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4132680
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8580983
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6727580
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.026883
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5639879
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3778778
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.3877678
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.91482
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6914580